Anixa Biosciences

ANIX

市值 US$9282萬

Dr. Jose Conejo-Garcia will speak on immunotherapy for ovarian cancer at the November 2–3 conference SAN JOSE, Calif., Oct. 13, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that Jose Conejo-Garcia, MD, PhD, inventor of Anixa's CAR-T therapy for ovarian cancer, will deliver a keynote presentation at the 2026 Ovarian Cancer Midwest Focus Conference.

First patient in current dose cohort exhibited no progression of her cancer three months aftertreatment Multiple patients have survived more than one year, including one beyond two years No dose-limiting toxicities observed to date SAN JOSE, Calif., Oct. 5, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that a patient in its ongoing Phase 1, dose-escalating, clinical trial evaluating its novel FSHR-targeted CAR-T therapy for recurrent ovarian cancer, exhibited stable disease 90 days after treatment.

Multiple Patients Surviving More Than One Year, Including One Beyond Two Years, With No Dose-Limiting Toxicities Observed to Date Patients in Cohort 5 Will Receive 1×10⁷ CAR-Positive Cells/kg Following Lymphodepletion SAN JOSE, Calif., Oct. 1, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the second patient has been treated in the fifth cohort of its ongoing Phase 1, dose-escalating, clinical trial (ClinicalTrials.gov NCT05316129) evaluating its novel FSHR-targeted CAR-T therapy for recurrent ovarian cancer.

Composition of matter patent secures exclusive protection for Anixa's breast cancer vaccine in Australia through 2040, expanding the Company's growing global IP estate Continues expansion of global intellectual property coverage in markets with increasing breast cancer incidence rates SAN JOSE, Calif., Sept. 21, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that IP Australia has issued Patent Number 2020221280 related to Anixa's breast cancer vaccine technology, exclusively licensed from Cleveland Clinic.

SAN JOSE, Calif., Sept. 16, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced the appointment of Carmen Guerra, M.D.

SAN JOSE, Calif., Sept. 9, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that an interview of Chairman and CEO, Dr. Amit Kumar, and breast cancer vaccine clinical trial patient, Sherie Steinberg, will air on the RedChip Small Stocks, Big Money™ show on Bloomberg TV this Saturday, September 12, at 7:00 PM ET.

Presentation to highlight Anixa's clinical progress and collaborations with leading cancer research institutions — Cleveland Clinic and Moffitt Cancer Center SAN JOSE, Calif., Sept. 3, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that Dr. Amit Kumar, Chairman and CEO, has been invited to speak at the Nasdaq & LD Micro Inaugural SF Summit on Wednesday, September 9, 2026, at Nasdaq's San Francisco headquarters.

Breast cancer vaccine final Phase 1 data shows all primary endpoints were met and protocol-defined immune responses in 74% of participants—Phase 2 preparations ongoing Ovarian cancer CAR-T therapy, lira-cel, advances to highest dose level to date in fifth cohort with lymphodepletion—four patients surpass one year of survival, longest at approximately 28 months Presentation to highlight Anixa's clinical progress and collaborations with leading cancer research institutions— Cleveland Clinic and Moffitt Cancer Center SAN JOSE, Calif., Aug. 24, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that management will participate in the 2026 Cantor Fitzgerald Global Healthcare Conference being held September 9 – 11, 2026, in New York City.

Ovarian cancer CAR-T therapy, lira-cel, advances to highest dose level to date in fifth cohort with lymphodepletion—four patients surpass one year of survival, longest at approximately 28 months Breast cancer vaccine final Phase 1 data shows all primary endpoints were met and protocol-defined immune responses in 74% of participants—Phase 2 preparations ongoing Presentation to highlight Anixa's clinical progress and collaborations with leading cancer research institutions—Moffitt Cancer Center and Cleveland Clinic SAN JOSE, Calif., Aug. 18, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that management will participate in the H.C.

Anixa Biosciences (ANIX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).